Drug intelligence / Profile preview

Streptococcus pneumoniae type 14 capsular polysaccharide antigen

Development stage
Unknown
Lead developer
Pfizer
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

Streptococcus pneumoniae type 14 capsular polysaccharide antigen is a highly purified bacterial carbohydrate derived from the capsule of Streptococcus pneumoniae serotype 14. It serves as an immunogenic component in vaccines, stimulating the host immune system to produce protective antibodies against invasive pneumococcal diseases such as pneumonia and bacteremia. The antigen can be used alone or conjugated to carrier proteins (such as tetanus toxoid) to enhance immunogenicity, especially in young children. Its mechanism of action is based on inducing a specific antibody response targeting the bacterial capsule, thereby preventing infection by facilitating opsonization and clearance of the pathogen[2][5][8]. This antigen is included in multivalent pneumococcal vaccines for active immunization.

Other names
pneumococcal polysaccharide type 14Pn14PSPn-14PSPn 14PSS. pneumoniae serotype 14 CPSrecombinant streptococcus pneumoniae type 14 capsular polysaccharide antigen
02

Targets

BCR (Immunoglobulin G B Cell Receptor)CPS14 (Streptococcus pneumoniae serotype 14 capsular polysaccharide)

Beyond the preview

Go deeper on Streptococcus pneumoniae type 14 capsular polysaccharide antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae type 14 capsular polysaccharide antigen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call